116 related articles for article (PubMed ID: 28274810)
1. Non-clinical safety evaluation and risk assessment to human of aleglitazar, a dual PPAR α/γ agonist, and its major human metabolite.
Bopst M; Atzpodien EA
Regul Toxicol Pharmacol; 2017 Jun; 86():107-116. PubMed ID: 28274810
[TBL] [Abstract][Full Text] [Related]
2. Nonclinical safety evaluation of muraglitazar, a novel PPARalpha/gamma agonist.
Waites CR; Dominick MA; Sanderson TP; Schilling BE
Toxicol Sci; 2007 Nov; 100(1):248-58. PubMed ID: 17675651
[TBL] [Abstract][Full Text] [Related]
3. Metabolism, excretion, and pharmacokinetics of [14c]-radiolabeled aleglitazar: a phase I, nonrandomized, open-label, single-center, single-dose study in healthy male volunteers.
Sturm S; Seiberling M; Weick I; Paehler A; Funk C; Ruf T
Clin Ther; 2012 Feb; 34(2):420-9. PubMed ID: 22244809
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic potential of the dual peroxisome proliferator activated receptor (PPAR)α/γ agonist aleglitazar in attenuating TNF-α-mediated inflammation and insulin resistance in human adipocytes.
Massaro M; Scoditti E; Pellegrino M; Carluccio MA; Calabriso N; Wabitsch M; Storelli C; Wright M; De Caterina R
Pharmacol Res; 2016 May; 107():125-136. PubMed ID: 26976796
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics, efficacy and safety of aleglitazar for the treatment of type 2 diabetes with high cardiovascular risk.
Younk LM; Uhl L; Davis SN
Expert Opin Drug Metab Toxicol; 2011 Jun; 7(6):753-63. PubMed ID: 21521130
[TBL] [Abstract][Full Text] [Related]
6. Rodent carcinogenicity profile of the antidiabetic dual PPAR alpha and gamma agonist muraglitazar.
Tannehill-Gregg SH; Sanderson TP; Minnema D; Voelker R; Ulland B; Cohen SM; Arnold LL; Schilling BE; Waites CR; Dominick MA
Toxicol Sci; 2007 Jul; 98(1):258-70. PubMed ID: 17426106
[TBL] [Abstract][Full Text] [Related]
7. Aleglitazar, a dual peroxisome proliferator-activated receptor-α and -γ agonist, protects cardiomyocytes against the adverse effects of hyperglycaemia.
Chen Y; Chen H; Birnbaum Y; Nanhwan MK; Bajaj M; Ye Y; Qian J
Diab Vasc Dis Res; 2017 Mar; 14(2):152-162. PubMed ID: 28111985
[TBL] [Abstract][Full Text] [Related]
8. Comparative transcriptional network modeling of three PPAR-α/γ co-agonists reveals distinct metabolic gene signatures in primary human hepatocytes.
Deehan R; Maerz-Weiss P; Catlett NL; Steiner G; Wong B; Wright MB; Blander G; Elliston KO; Ladd W; Bobadilla M; Mizrahi J; Haefliger C; Edgar A
PLoS One; 2012; 7(4):e35012. PubMed ID: 22514701
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic potential of aleglitazar, a new dual PPAR-α/γ agonist: implications for cardiovascular disease in patients with diabetes mellitus.
Cavender MA; Lincoff AM
Am J Cardiovasc Drugs; 2010; 10(4):209-16. PubMed ID: 20653327
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular Risk and Safety Evaluation of a Dual Peroxisome Proliferator-Activated Receptor-Alpha/Gamma Agonist, Aleglitazar, in Patients With Type 2 Diabetes: A Meta-analysis.
Han CL; Qu CZ
J Cardiovasc Pharmacol; 2020 Apr; 75(4):351-357. PubMed ID: 31929323
[TBL] [Abstract][Full Text] [Related]
11. Effects of aleglitazar, a balanced dual peroxisome proliferator-activated receptor α/γ agonist on glycemic and lipid parameters in a primate model of the metabolic syndrome.
Hansen BC; Tigno XT; Bénardeau A; Meyer M; Sebokova E; Mizrahi J
Cardiovasc Diabetol; 2011 Jan; 10():7. PubMed ID: 21251281
[TBL] [Abstract][Full Text] [Related]
12. Aleglitazar, a balanced PPARα/γ agonist, has no clinically relevant pharmacokinetic interaction with high-dose atorvastatin or rosuvastatin.
Foley-Comer AJ; Young AM; Russell-Yarde F; Jordan P
Expert Opin Investig Drugs; 2011 Jan; 20(1):3-12. PubMed ID: 21114416
[TBL] [Abstract][Full Text] [Related]
13. Effects of the dual peroxisome proliferator-activated receptor-α/γ agonist aleglitazar on renal function in patients with stage 3 chronic kidney disease and type 2 diabetes: a Phase IIb, randomized study.
Ruilope L; Hanefeld M; Lincoff AM; Viberti G; Meyer-Reigner S; Mudie N; Wieczorek Kirk D; Malmberg K; Herz M
BMC Nephrol; 2014 Nov; 15():180. PubMed ID: 25407798
[TBL] [Abstract][Full Text] [Related]
14. Effects of the dual PPAR-α/γ agonist aleglitazar on glycaemic control and organ protection in the Zucker diabetic fatty rat.
Bénardeau A; Verry P; Atzpodien EA; Funk JM; Meyer M; Mizrahi J; Winter M; Wright MB; Uhles S; Sebokova E
Diabetes Obes Metab; 2013 Feb; 15(2):164-74. PubMed ID: 22958363
[TBL] [Abstract][Full Text] [Related]
15. Exposure and response analysis of aleglitazar on cardiovascular risk markers and safety outcomes: An analysis of the AleCardio trial.
Koomen JV; Heerspink HJL; Schrieks IC; Schwartz GG; Lincoff AM; Nicholls SJ; Svensson A; Wedel H; Weichert A; Grobbee DE; Stevens J
Diabetes Obes Metab; 2020 Jan; 22(1):30-38. PubMed ID: 31468659
[TBL] [Abstract][Full Text] [Related]
16. Comparative molecular profiling of the PPARα/γ activator aleglitazar: PPAR selectivity, activity and interaction with cofactors.
Dietz M; Mohr P; Kuhn B; Maerki HP; Hartman P; Ruf A; Benz J; Grether U; Wright MB
ChemMedChem; 2012 Jun; 7(6):1101-11. PubMed ID: 22489042
[TBL] [Abstract][Full Text] [Related]
17. Dual PPARα/γ agonist aleglitazar confers stroke protection in a model of mild focal brain ischemia in mice.
Boujon V; Uhlemann R; Wegner S; Wright MB; Laufs U; Endres M; Kronenberg G; Gertz K
J Mol Med (Berl); 2019 Aug; 97(8):1127-1138. PubMed ID: 31147725
[TBL] [Abstract][Full Text] [Related]
18. The effect of aleglitazar on the pharmacokinetics and pharmacodynamics of S- and R-warfarin in healthy male subjects.
Sanwald-Ducray P; Jamois C; Banken L
J Cardiovasc Pharmacol; 2014 Feb; 63(2):152-7. PubMed ID: 24157957
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of muraglitazar (BMS-298585), a dual peroxisome proliferator-activated receptors (PPAR) alpha and gamma activator, in mice, rats, dogs, and monkeys.
Hosagrahara VP; Chandrasena G; Chang SY; Koplowitz B; Hariharan N; Cheng PT; Humphreys WG
Xenobiotica; 2006 Dec; 36(12):1227-38. PubMed ID: 17162469
[TBL] [Abstract][Full Text] [Related]
20. Effects of the dual peroxisome proliferator-activated receptor activator aleglitazar in patients with Type 2 Diabetes mellitus or prediabetes.
Erdmann E; Califf R; Gerstein HC; Malmberg K; Ruilope L; Schwartz GG; Wedel H; Volz D; Ditmarsch M; Svensson A; Bengus M
Am Heart J; 2015 Jul; 170(1):117-22. PubMed ID: 26093872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
